Organisation paid for research Program year 2025 Source: CMS Open Payments

Grace Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$525,876

574 payments

Through program year 2025, Grace Research, LLC is reported as receiving $525,876 in research payments, across 574 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$179,074	109
2024	Research	$57,673	56
2023	Research	$150,500	103
2022	Research	$57,928	214
2021	Research	$26,470	14
2020	Research	$30,203	28
2019	Research	$24,028	50

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $152,811 9 payments
Boehringer Ingelheim International GmbH $117,412 181 payments
Novo Nordisk AS $92,955 239 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $66,092 13 payments
Novo Nordisk Inc $53,875 127 payments
Novartis Pharmaceuticals Corporation $41,231 3 payments
Kowa Research Institute, Inc. $1,500 2 payments

Studies the money was for Research payments · program years 2019–2025

20170625_Vesalius - CV $94,089 4 payments
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) $86,946 89 payments
Ex9536-4773 $67,939 225 payments
Das-7537 $53,875 127 payments
Empagliflozin and heart failure (HFpEF) $44,669 83 payments
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke $42,878 2 payments
BI 690517+Empa - Placebo+Empa in patients w. HF (LVEF) $25,181 3 payments
Ex9536-4665 $25,016 14 payments
Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $24,669 1 payment
Empagliflozin for prevention of HHF and death after an AMI $18,688 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.